Clinical evaluation of temocillin in urinary tract infections.
A group of 27 female and 2 male urological patients, aged 19 to 80 years (mean 44 years), were treated with intravenous temocillin 500 mg twice daily for 5 to 7 days. The diagnoses were acute pyelonephritis (n = 20), acute cystitis (n = 6), and acute cystitis and pyelonephritis combined (3). The causative organisms were Escherichia coli (n = 20). Proteus species (n = 9). Klebsiella species (n = 4). Streptococcus faecalis (n = 2). Staphylococcus epidermidis (n = 1), and Providencia stuartii (n = 1). 27 of the 29 patients (93%) were clinically and bacteriologically cured; bacteriuria persisted in 2 patients with prolonged obstructive uropathy. In acute non-obstructive pyelonephritis, the urinary excretion of beta-2-microglobulin rapidly decreased, documenting a prompt renal tubular restitution during therapy. The drug was well tolerated and proved very safe with regard to haematological, hepatic and renal parameters. Also, Candida haemagglutination titres did not increase significantly during therapy. Temocillin therapy should preferably be commenced after the results of the urine culture are available.
D000328:Adult; D000368:Aged; D003556:Cystitis / Q000188:drug therapy; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007684:Kidney Tubules / Q000502:physiology; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy; D011704:Pyelonephritis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D010406:Penicillins; C031367:temocillin